Leerink Cuts Moderna Price Target to $17 After Recordati Collaboration
Leerink Partners lowered its price target for Moderna to $17 from $18 and retained an Underperform rating after the company disclosed a commercialization collaboration with Italian drugmaker Recordati for mRNA-3927, an investigational therapy for propionic acidemia. The new target sits well below Moderna's prevailing market price and reflects Leeri…